Free Trial

Cambridge Cognition (COG) Competitors

Cambridge Cognition logo
GBX 42.40 +0.40 (+0.95%)
As of 01/21/2025 10:40 AM Eastern

COG vs. KOO, RENX, INHC, TRLS, IQAI, FDBK, DVRG, SENS, EMIS, and CRW

Should you be buying Cambridge Cognition stock or one of its competitors? The main competitors of Cambridge Cognition include Kooth (KOO), Renalytix (RENX), Induction Healthcare Group (INHC), Trellus Health (TRLS), IQ-AI (IQAI), Feedback (FDBK), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.

Cambridge Cognition vs.

Kooth (LON:KOO) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

Kooth has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Cambridge Cognition has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Cambridge Cognition received 95 more outperform votes than Kooth when rated by MarketBeat users. However, 90.91% of users gave Kooth an outperform vote while only 44.30% of users gave Cambridge Cognition an outperform vote.

CompanyUnderperformOutperform
KoothOutperform Votes
10
90.91%
Underperform Votes
1
9.09%
Cambridge CognitionOutperform Votes
105
44.30%
Underperform Votes
132
55.70%

65.0% of Kooth shares are owned by institutional investors. Comparatively, 35.2% of Cambridge Cognition shares are owned by institutional investors. 17.3% of Kooth shares are owned by insiders. Comparatively, 29.9% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£54.17M1.20£4.28M£0.121,483.33
Cambridge Cognition£13.08M1.36-£1.32M-£0.04-1,060.00

Kooth has a net margin of 7.89% compared to Cambridge Cognition's net margin of -10.07%. Kooth's return on equity of 23.83% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth7.89% 23.83% 10.12%
Cambridge Cognition -10.07%-74.36%-0.30%

Kooth presently has a consensus target price of GBX 585, suggesting a potential upside of 228.65%. Given Kooth's stronger consensus rating and higher probable upside, equities research analysts plainly believe Kooth is more favorable than Cambridge Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kooth had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Kooth and 1 mentions for Cambridge Cognition. Kooth's average media sentiment score of 1.13 beat Cambridge Cognition's score of 0.54 indicating that Kooth is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kooth
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cambridge Cognition
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Kooth beats Cambridge Cognition on 14 of the 18 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Sign up to receive the latest news and ratings for COG and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COG vs. The Competition

MetricCambridge CognitionHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£17.78M£200.65M£5.39B£2.04B
Dividend YieldN/A6.94%5.37%5.16%
P/E Ratio-1,060.00537.3688.911,926.65
Price / Sales1.36828.491,280.48384,006.48
Price / Cash4.3147.1436.6029.21
Price / Book7.075.404.963.08
Net Income-£1.32M-£8.11M£117.89M£183.60M
7 Day Performance6.83%1.08%1.68%1.24%
1 Month Performance32.50%14.22%3.63%3.43%
1 Year Performance-14.69%13.13%26.16%43.35%

Cambridge Cognition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COG
Cambridge Cognition
N/AGBX 42.40
+1.0%
N/A-14.3%£17.78M£13.08M-1,060.0080News Coverage
KOO
Kooth
3.0371 of 5 stars
GBX 176.27
-2.3%
GBX 585
+231.9%
-39.0%£64.30M£54.17M1,468.92478Positive News
RENX
Renalytix
N/AGBX 11.56
-3.7%
N/A+1.3%£19.17M£2.29M-48.15102Gap Down
INHC
Induction Healthcare Group
N/AGBX 8.50
flat
N/A-56.2%£7.98M£13.65M-283.3374
TRLS
Trellus Health
N/AGBX 2.80
+366.7%
N/A-50.0%£4.52M£35,000.00-93.3331Gap Up
High Trading Volume
IQAI
IQ-AI
N/AGBX 1.57
-1.6%
N/A-46.9%£3.48M£538,190.00-13.676
FDBK
Feedback
N/AGBX 19.63
-5.6%
N/A-71.3%£2.62M£1.18M-78.5224
DVRG
DeepVerge
N/AN/AN/AN/A£1.14M£12.41M-15.0073
SENS
Sensyne Health
N/AN/AN/AN/A£583,000.00£7.81M-0.0270Gap Down
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
CRW
Craneware
1.9189 of 5 stars
GBX 2,080
-1.4%
GBX 2,700
+29.8%
+3.6%£735.07M£189.27M8,000.00734

Related Companies and Tools


This page (LON:COG) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners